Clinical Evidence
Psoriasis-Prone Skin
Clinical Study Overview
XTRIMOIST-PS Moisturizing Lotion was evaluated in a clinical study conducted on participants with mild to moderate Psoriasis.
Topical steroid treatment
alone
Topical steroid therapy + XTRIMOIST-PS Moisturizing Lotion
Study Duration
4 Week
Study Design
Monocentric, parallel-group clinical study
Key Clinical Findings
Significant Reduction in Psoriasis Severity
Participants using XTRIMOIST-PS Moisturizing Lotion alongside topical steroid therapy demonstrated significantly greater improvement in psoriasis symptoms compared to steroid therapy alone.
Clinical Results After4 Weeks:
- 26.8% reduction in PSI score
(PSI = Psoriasis Severity Index, a standard clinical assessment for psoriasis severity.)
Intensive Skin
Hydration
Clinical measurements showed a substantial improvement in skin hydration levels.
Clinical Results
- Up to 213% increase in skin hydration within 1 hour
- 127% increase in hydration after 4 weeks
Hydration levels were measured using MoistureMeter SC, an advanced scientific skin hydration assessment device.
Improved Skin Barrier Function
XTRIMOIST-PS demonstrated significant improvement in skin barrier integrity by reducing Trans Epidermal Water Loss (TEWL).
Clinical Results
- 19.3% reduction in TEWL within 1 hour
- 14.3% reduction in TEWL after 4 weeks
Lower TEWL indicates stronger skin barrier protection and reduced moisture loss.
Clinically Proven Itch Relief
Participants experienced significant improvement in itching associated with psoriasis.
Clinical Results
- Up to 97.1% reduction in itching scores after 4 weeks
- Significantly greater itch relief compared to steroid therapy alone
Participant Satisfaction After 4 Weeks of use:
had reduced
more hydrated
had reduced
product overall
Safety & Tolerance
XTRIMOIST-PS Moisturizing Lotion was found to be well tolerated
throughout the study.
Clinical Safety Findings:
- No adverse events reported
- No irritation, burning, tingling, or pricking sensations observed
- Excellent skin compatibility throughout 4 weeks of use
Quality of Life Improvement
- Skin comfort
- Daily activities
- Social confidence
- Work and lifestyle comfort
After 4 weeks:
- No participants reported severe skin discomfort
- No participants reported psoriasis significantly affecting work or social life
Clinical assessments showed meaningful improvement in daily quality of life for participants using XTRIMOIST-PS.
Conclusion
- 26.8% Psoriasis Severity
- 127% increase in hydration
- 14.3% reduction after 4 weeks
- Up to 97.1% reduction in itching
- Scaling reduction & Increase in overall skin comfort
Clinical evaluation demonstrated that XTRIMOIST-PS Moisturizing Lotion, when used alongside topical steroid therapy, provided significant improvement in compared to topical steroid theraph alone.